313 related articles for article (PubMed ID: 21255370)
1. Shiga toxin and its use in targeted cancer therapy and imaging.
Engedal N; Skotland T; Torgersen ML; Sandvig K
Microb Biotechnol; 2011 Jan; 4(1):32-46. PubMed ID: 21255370
[TBL] [Abstract][Full Text] [Related]
2. Blood group P1 antigen-bearing glycoproteins are functional but less efficient receptors of Shiga toxin than conventional glycolipid-based receptors.
Morimoto K; Suzuki N; Tanida I; Kakuta S; Furuta Y; Uchiyama Y; Hanada K; Suzuki Y; Yamaji T
J Biol Chem; 2020 Jul; 295(28):9490-9501. PubMed ID: 32409578
[TBL] [Abstract][Full Text] [Related]
3. Endocytosis and retrograde transport of Shiga toxin.
Sandvig K; Bergan J; Dyve AB; Skotland T; Torgersen ML
Toxicon; 2010 Dec; 56(7):1181-5. PubMed ID: 19951719
[TBL] [Abstract][Full Text] [Related]
4. Globotriaosylceramide (Gb3) content in HeLa cells is correlated to Shiga toxin-induced cytotoxicity and Gb3 synthase expression.
Shin IS; Ishii S; Shin JS; Sung KI; Park BS; Jang HY; Kim BW
BMB Rep; 2009 May; 42(5):310-4. PubMed ID: 19470247
[TBL] [Abstract][Full Text] [Related]
5. Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit.
Geyer PE; Maak M; Nitsche U; Perl M; Novotny A; Slotta-Huspenina J; Dransart E; Holtorf A; Johannes L; Janssen KP
Mol Cancer Ther; 2016 May; 15(5):1008-17. PubMed ID: 26826119
[TBL] [Abstract][Full Text] [Related]
6. Glycosphingolipid requirements for endosome-to-Golgi transport of Shiga toxin.
Raa H; Grimmer S; Schwudke D; Bergan J; Wälchli S; Skotland T; Shevchenko A; Sandvig K
Traffic; 2009 Jul; 10(7):868-82. PubMed ID: 19453975
[TBL] [Abstract][Full Text] [Related]
7. Shiga Toxin (Stx) Classification, Structure, and Function.
Melton-Celsa AR
Microbiol Spectr; 2014 Aug; 2(4):EHEC-0024-2013. PubMed ID: 25530917
[TBL] [Abstract][Full Text] [Related]
8. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells.
Warnier M; Römer W; Geelen J; Lesieur J; Amessou M; van den Heuvel L; Monnens L; Johannes L
Kidney Int; 2006 Dec; 70(12):2085-91. PubMed ID: 17063173
[TBL] [Abstract][Full Text] [Related]
9. Protection against Shiga Toxins.
Kavaliauskiene S; Dyve Lingelem AB; Skotland T; Sandvig K
Toxins (Basel); 2017 Feb; 9(2):. PubMed ID: 28165371
[TBL] [Abstract][Full Text] [Related]
10. Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation.
Storck W; Meisen I; Gianmoena K; Pläger I; Kouzel IU; Bielaszewska M; Haier J; Mormann M; Humpf HU; Karch H; Müthing J
Biol Chem; 2012 Aug; 393(8):785-99. PubMed ID: 22944681
[TBL] [Abstract][Full Text] [Related]
11. The ether lipid precursor hexadecylglycerol protects against Shiga toxins.
Bergan J; Skotland T; Lingelem AB; Simm R; Spilsberg B; Lindbäck T; Sylvänne T; Simolin H; Ekroos K; Sandvig K
Cell Mol Life Sci; 2014 Nov; 71(21):4285-300. PubMed ID: 24740796
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Uses of Bacterial Subunit Toxins.
Lingwood C
Toxins (Basel); 2021 May; 13(6):. PubMed ID: 34073185
[TBL] [Abstract][Full Text] [Related]
13. Shiga toxin binding alters lipid packing and the domain structure of Gb
Bosse M; Sibold J; Scheidt HA; Patalag LJ; Kettelhoit K; Ries A; Werz DB; Steinem C; Huster D
Phys Chem Chem Phys; 2019 Jul; 21(28):15630-15638. PubMed ID: 31268447
[TBL] [Abstract][Full Text] [Related]
14. Membrane invagination induced by Shiga toxin B-subunit: from molecular structure to tube formation.
Pezeshkian W; Hansen AG; Johannes L; Khandelia H; Shillcock JC; Kumar PB; Ipsen JH
Soft Matter; 2016 Jun; 12(23):5164-71. PubMed ID: 27070906
[TBL] [Abstract][Full Text] [Related]
15. Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature.
Bauwens A; Betz J; Meisen I; Kemper B; Karch H; Müthing J
Cell Mol Life Sci; 2013 Feb; 70(3):425-57. PubMed ID: 22766973
[TBL] [Abstract][Full Text] [Related]
16. Rapid method to detect shiga toxin and shiga-like toxin I based on binding to globotriosyl ceramide (Gb3), their natural receptor.
Ashkenazi S; Cleary TG
J Clin Microbiol; 1989 Jun; 27(6):1145-50. PubMed ID: 2666433
[TBL] [Abstract][Full Text] [Related]
17. Intracellular drug delivery: Potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy.
Luginbuehl V; Meier N; Kovar K; Rohrer J
Biotechnol Adv; 2018; 36(3):613-623. PubMed ID: 29432805
[TBL] [Abstract][Full Text] [Related]
18. Activation of Src family kinase yes induced by Shiga toxin binding to globotriaosyl ceramide (Gb3/CD77) in low density, detergent-insoluble microdomains.
Katagiri YU; Mori T; Nakajima H; Katagiri C; Taguchi T; Takeda T; Kiyokawa N; Fujimoto J
J Biol Chem; 1999 Dec; 274(49):35278-82. PubMed ID: 10575015
[TBL] [Abstract][Full Text] [Related]
19. Tumor delivery of ultrasound contrast agents using Shiga toxin B subunit.
Couture O; Dransart E; Dehay S; Nemati F; Decaudin D; Johannes L; Tanter M
Mol Imaging; 2011 Apr; 10(2):135-43. PubMed ID: 21439258
[TBL] [Abstract][Full Text] [Related]
20. Toll-like receptor 4 facilitates binding of Shiga toxin to colon carcinoma and primary umbilical vein endothelial cells.
Torgersen ML; Engedal N; Pedersen AM; Husebye H; Espevik T; Sandvig K
FEMS Immunol Med Microbiol; 2011 Feb; 61(1):63-75. PubMed ID: 21054580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
